Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: Is treatment response different between children and adolescents?

Child and Adolescent Psychiatry and Mental Health

Volumn 5, Issue , 2011, Pages

  Berek, Michael ^a   Kordon, Andreas ^b   Hargarter, Ludger ^c   Mattejat, Fritz ^d   Slawik, Lara ^c   Rettig, Klaus ^e   Schäuble, Barbara ^c  

^a Praxis für Kinder und Jugendpsychiatrie ^*  (Germany)

^b Klinik fur Psychiatrie und Psychotherapie   (Germany)

^c JANSSEN CILAG GMBH   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e G E M Gesellschaft für Evaluation und Qualitätssicherung in der Medizin mbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; OROS; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACADEMIC ACHIEVEMENT; ADOLESCENT; ADULT; AGGRESSION; ANOREXIA; ANXIETY; APATHY; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHILD; CLINICAL ASSESSMENT; CONTROLLED STUDY; DEPRESSION; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FEMALE; HEADACHE; HUMAN; INDIVIDUALIZATION; INSOMNIA; INTERVENTION STUDY; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MUSCLE CONTRACTION; MUSCLE SPASM; NAUSEA; NERVOUSNESS; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SAFETY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TREATMENT RESPONSE; VITAL SIGN; WEIGHT REDUCTION;

EID: 79960675506     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-5-26     Document Type: Article

References (37)

1. Wilens TE, Dodson W. A clinical perspective of attention-deficit/hyperactivity disorder into adulthood. J Clin Psychiatry 2004, 65:1301-1313. 10.4088/JCP.v65n1003, 15491232.
2. Barkley RA, Fischer M, Smallish L, Fletcher K. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry 2006, 45:192-202. 10.1097/01.chi.0000189134.97436.e2, 16429090.
3. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr 2007, 28(4):265-273. 10.1097/DBP.0b013e31811ff87d, 17700078.
4. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000, 157:816-818. 10.1176/appi.ajp.157.5.816, 10784477.
5. Kooij SJ, Bejerot S, Blackwell A, Caci H, Casas-Brugué M, Carpentier PJ, Edvinsson D, Fayyad J, Foeken K, Fitzgerald M, Gaillac V, Ginsberg Y, Henry C, Krause J, Lensing MB, Manor I, Niederhofer H, Nunes-Filipe C, Ohlmeier MD, Oswald P, Pallanti S, Pehlivanidis A, Ramos-Quiroga JA, Rastam M, Ryffel-Rawak D, Stes S, Asherson P. European consensus statement on diagnosis and treatment of adult ADHD: The European Network Adult ADHD. BMC Psychiatry 2010, 10:67. 10.1186/1471-244X-10-67, 2942810, 20815868.
6. Owens EB, Hinshaw SP, Lee SS, Lahey BB. Few girls with childhood attention-deficit/hyperactivity disorder show positive adjustment during adolescence. J Clin Child Adolesc Psychol 2009, 38(1):132-143. 10.1080/15374410802575313, 2940934, 19130363.
7. Lee SS, Lahey BB, Owens EB, Hinshaw SP. Few preschool boys and girls with ADHD are well adjusted during adolescence. J Abnorm Child Psychol 2008, 36:373-383. 10.1007/s10802-007-9184-6, 17914666.
8. Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B. Exploring the impact of once-daily OROS methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgrad Med 2011,
9. Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B. Transitioning to OROS methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Rev Neurother 2011, 11(4):499-508. 10.1586/ern.11.18, 21469923.
10. Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Schäuble B. Transitioning from extended-release methylphenidate (MPH) onto OROS MPH improves symptoms, functionality and quality of life in children/adolescents with ADHD: results of a 3-month non-interventional study. Current Medical Research Opinion 2011,
11. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, . American Academy of Child and Adolescent Psychiatry Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 2002, 41(2 Suppl):26S-49S. American Academy of Child and Adolescent Psychiatry.
12. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs 2003, 17:117-131. 10.2165/00023210-200317020-00004, 12521359.
13. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, Lindemulde E, Wigal S. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003, 60:204-211. 10.1001/archpsyc.60.2.204, 12578439.
14. Remschmidt H, Hoare P, Ettrich C, Rothenberger A, Santosh P, Schmidt M, Spender Q, Tamhne R, Thompson M, Tinline C, Trott GE, Medori R. Symptom control in children and adolescents with attention-deficit/hyperactivity disorder on switching from immediate-release MPH to OROS® MPH. Results of a 3-week open-label study. Eur Child Adolesc Psychiatry 2005, 14:297-304. 10.1007/s00787-005-0467-6, 16220213.
15. Coghill D, Seth S. Osmotic, controlled-release methylphenidate for the treatment of ADHD. Expert Opin Pharmacother 2006, 7:2119-2139. 10.1517/14656566.7.15.2119, 17020437.
16. Wigal SB, Wigal T, Schuck S, Brams M, Williamson D, Armstrong RB, Starr HL. Academic, behavioral, and cognitive effects of OROS® methylphenidate on older children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011, 21:121-131. Epub 2011 Apr 13, 10.1089/cap.2010.0047, 21488750.
17. Coghill D, Soutullo C, d'Aubuisson C, Preuss U, Lindback T, Silverberg M, Buitelaar J. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health 2008, 2:31. 10.1186/1753-2000-2-31, 2588557, 18957105.
18. Erhardt D, Hinshaw SP. Initial sociometric impressions of attention-deficit hyperactivity disorder and comparison boys: predictions from social behaviors and from nonbehavioral variables. J Consult Clin Psychol 1994, 62:833-842.
19. Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics 2005, 116:e364-369. 10.1542/peds.2005-0386, 16140679.
20. Danckaerts M, Sonuga-Barke EJS, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, Santosh P, Rothenberger A, Sergeant J, Steinhausen H-C, Talor E, Zuddas A, Coghill D. The quality of life of children with attention deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry 2010, 19:83-105. 10.1007/s00787-009-0046-3, 19633992.
21. Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J Clin Psychiatry 1998, 59(suppl 7):24-30.
22. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr Clin North Am 1999, 46:857-870. 10.1016/S0031-3955(05)70159-0, 10570692.
23. Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners' parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998, 26:257-268. 10.1023/A:1022602400621, 9700518.
24. Mattejat F, Jungmann J, Meusers M, Moik C, Nölkel P, Schaff C, Scholz M, Schmidt M-H, Remschmidt H. Das Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK) - Eine Pilotstudie. Z Kinder Jugendpsychiatr Psycother 1998, 26:174-182.
25. Mattejat F, Remschmidt H. Zur Erfassung der Lebensqualität bei psychisch gestörten Kindern und Jugendlichen - Eine Übersicht. [Assessing the quality of life of children and adolescents with psychiatric disorders - an overview]. Z Kinder Jugendpsychiatr Psycother 1998, 26:183-196.
26. Mattejat F, Simon B, König U, Quaschner K, Barchewitz C, Felbel D, Herpertz-Dahlmann B, Höhne D, Janthur B, Jungmann J, Katzenski B, Naumann A, Nölkel P, Schaff C, Schulz E, Warnke A, Weinand F, Remschmidt H. Lebensqualität bei psychisch kranken Kindern und Jugendlichen. Z Kinder Jugendpsychiatr Psycother 2003, 31:293-303.
27. Ehnis P, Trosse M, Remschmidt H. Life quality of children and adolescents in Germany. Results of a representative telephone survey [abstract]. 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions: 22-26 August 2004 2004, 374. Steinkopf, Remschmidt H, Belfer M.
28. Jozefiak T, Larsson B, Wichstrøm L, Mattejat F, Ravens-Sieberer U. Quality of life as reported by school children and their parents: a cross-sectional survey. Health and Quality of Life Outcomes 2008, 6:34-45. 10.1186/1477-7525-6-34, 2409303, 18489777.
29. Mattejat F, Remschmidt H. Das Inventar zur Erfassung der Lebensqualität bei Kindern und Jugendlichen (ILK) [The inventory of life quality in children and adolescents (ILC)]. 2006, Verlag Hans Huber, Bern.
30. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983, 40:1228-1231.
31. Wehmeier PM, Schacht A, Escobar R, Savill N, Harpin V. Differences between children and adolescents in treatment response to atomoxetine and the correlation between health-related quality of life and Attention Deficit/Hyperactivity Disorder core symptoms: Meta-analysis of five atomoxetine trials. Child Adolesc Psychiatry Ment Health 2010, 4:30. 10.1186/1753-2000-4-30, 3012018, 21134277.
32. Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004, 4:28. 10.1186/1471-244X-4-28, 524494, 15458569.
33. Chou W-J, Chou M-C, Tzang R-F, Hsu Y-C, Gau SS-F, Chen S-J, Wu Y-Y, Huang Y-F, Liang H-Y, Cheng H. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes. Psych Clin Neurosci 2009, 63:167-175.
34. Kim Y, Shin M-S, Kim J-W, Yoo H-J, Cho S-C, Kim B-N. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD. Hum Psychopharmacol Clin Exp 2009, 24:95-102.
35. Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ. Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 2007, 28(4):274-287. 10.1097/DBP.0b013e3180cabc28, 17700079.
36. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics 2009, 124(1):71-78. 10.1542/peds.2008-3347, 2954591, 19564285.
37. van den Ban E, Souverein PC, Swaab H, van Engeland H, Egberts TC, Heerdink ER. Less discontinuation of ADHD drug use since the availability of long-acting ADHD medication in children, adolescents and adults under the age of 45 years in the Netherlands. Atten Defic Hyperact Disord 2010, 2:213-220. Epub Nov 30, 2010, 10.1007/s12402-010-0044-9, 3000908, 21258431.